The number of affiliates of major conglomerates under S. Korea's antitrust watch list increased by 24 to reach 2,325 as of the end of October, with the groups expanding investments in digital content and financial firms.
The transactions that increased new affiliates under tight restrictions include KT Corp.'s acquisition of K-Bank, an online bank, and a Naver Corp. affiliate establishing four digital content firms.
KT Corp. is South Korea's largest fixed-line internet operator, while Naver Corp. is the leading online portal operator.
The business groups launched or acquired 56 new affiliates while offloading 32 others.
Affiliates of large conglomerates with assets exceeding 10 trillion won are restricted under the South Korean fair trade law from making equity investments in co-affiliated companies or offering loan guarantees to each other.
The conglomerates are prohibited from engaging in excessive trading among affiliates and are required to make public filings on their non-listed affiliates.


Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Google Secures Pentagon AI Deal for Classified Projects
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 



